• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名26岁男性的极重型再生障碍性贫血：对预后和治疗选择的影响

Very Severe Aplastic Anemia in a 26-Year-Old Male: Implications for Prognosis and Treatment Options.

作者信息

Alobaidi Ahmed, Albadry Ahmed, Murray Anne

机构信息

Internal Medicine, Methodist Health System, Dallas, USA.

Faculty of Medicine, Charles University in Prague, Prague, CZE.

出版信息

Cureus. 2023 Sep 22;15(9):e45750. doi: 10.7759/cureus.45750. eCollection 2023 Sep.

DOI:10.7759/cureus.45750
PMID:37872935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10590479/
Abstract

Aplastic anemia (AA) is a hematopoietic stem cell (HSC) disorder characterized by the loss of HSCs, bone marrow failure, and peripheral pancytopenia. AA is classified as very severe (VSAA), severe (SAA), or non-severe (NSAA) based on the severity criteria. This classification system has implications for the prognosis and treatment options offered to patients. The prognosis of AA has improved over the past several decades with the advancements in supportive care, HSC transplant (HCT), and immunosuppressive therapy (IST). In this report, we present the case of a 26-year-old male diagnosed with VSAA after presenting with severe neutropenia and fever. The patient ultimately underwent HSC transplantation.

摘要

再生障碍性贫血（AA）是一种造血干细胞（HSC）疾病，其特征为造血干细胞丧失、骨髓衰竭和外周血全血细胞减少。根据严重程度标准，AA分为极重型（VSAA）、重型（SAA）或非重型（NSAA）。该分类系统对患者的预后和治疗选择具有影响。随着支持治疗、造血干细胞移植（HCT）和免疫抑制治疗（IST）的进展，AA的预后在过去几十年中有所改善。在本报告中，我们介绍了一名26岁男性的病例，该患者在出现严重中性粒细胞减少和发热后被诊断为VSAA。患者最终接受了造血干细胞移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6391/10590479/6a09752d9d5b/cureus-0015-00000045750-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6391/10590479/6a09752d9d5b/cureus-0015-00000045750-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6391/10590479/6a09752d9d5b/cureus-0015-00000045750-i01.jpg

相似文献

1
Very Severe Aplastic Anemia in a 26-Year-Old Male: Implications for Prognosis and Treatment Options.一名26岁男性的极重型再生障碍性贫血：对预后和治疗选择的影响
Cureus. 2023 Sep 22;15(9):e45750. doi: 10.7759/cureus.45750. eCollection 2023 Sep.
2
Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?成人新诊断重型再生障碍性贫血的一线治疗选择：强化免疫抑制治疗加艾曲泊帕或同胞供者造血干细胞移植？
Transplant Cell Ther. 2022 Sep;28(9):586.e1-586.e7. doi: 10.1016/j.jtct.2022.05.027. Epub 2022 May 21.
3
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP).儿童获得性再生障碍性贫血的诊断与管理。意大利儿科血液肿瘤协会（AIEOP）骨髓衰竭研究组指南。
Blood Cells Mol Dis. 2015 Jun;55(1):40-7. doi: 10.1016/j.bcmd.2015.03.007. Epub 2015 Mar 31.
4
Interleukin-6 and interleukin-8 levels in children with aplastic anemia and its correlation with disease severity and response to immunosuppressive therapy.再生障碍性贫血患儿白细胞介素-6 和白细胞介素-8 水平及其与疾病严重程度和免疫抑制治疗反应的相关性。
Ann Afr Med. 2023 Oct-Dec;22(4):446-450. doi: 10.4103/aam.aam_106_22.
5
Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers.儿童获得性免疫抑制治疗后再生障碍性贫血的临床结局：中国南方两家三级医疗中心的13年经验
Int J Gen Med. 2021 Jul 2;14:3133-3144. doi: 10.2147/IJGM.S313898. eCollection 2021.
6
Epidemiology, Clinico-Haematological Profile and Management of Aplastic Anaemia: AIIMS Experience.再生障碍性贫血的流行病学、临床血液学特征及管理：全印医学科学研究所的经验
J Assoc Physicians India. 2015 Mar;63(3 Suppl):30-5.
7
Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.再生障碍性贫血（AA）患儿免疫抑制治疗（IST）后的复发与克隆性疾病：SAA 94研究经验。德国/奥地利儿童再生障碍性贫血工作组
Klin Padiatr. 1998 Jul-Aug;210(4):173-9. doi: 10.1055/s-2008-1043875.
8
Idiopathic aplastic anemia: diagnosis and classification.特发性再生障碍性贫血：诊断和分类。
Autoimmun Rev. 2014 Apr-May;13(4-5):569-73. doi: 10.1016/j.autrev.2014.01.014. Epub 2014 Jan 12.
9
Allogeneic Hematopoietic Stem Cell Transplant for Severe Aplastic Anemia: Current State and Future Directions.异基因造血干细胞移植治疗重型再生障碍性贫血：现状与未来方向
Curr Stem Cell Res Ther. 2018;13(5):350-355. doi: 10.2174/1574888X12666170227151226.
10
[Diagnosis and treatment of aquired aplastic anemia].[获得性再生障碍性贫血的诊断与治疗]
Ter Arkh. 2006;78(11):48-54.

引用本文的文献

1
More Than a Haematoma: A Case of Aplastic Anemia.不仅仅是血肿：一例再生障碍性贫血病例
Cureus. 2024 Dec 14;16(12):e75689. doi: 10.7759/cureus.75689. eCollection 2024 Dec.

本文引用的文献

1
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome.低增生性 MDS 的生物学和临床管理：MDS 作为一种骨髓衰竭综合征。
Best Pract Res Clin Haematol. 2021 Jun;34(2):101280. doi: 10.1016/j.beha.2021.101280. Epub 2021 Jun 26.
2
Approach to the diagnosis of aplastic anemia.再生障碍性贫血的诊断方法。
Blood Adv. 2021 Jun 22;5(12):2660-2671. doi: 10.1182/bloodadvances.2021004345.
3
Pathogenesis of aplastic anemia.再生障碍性贫血的发病机制。
Hematology. 2019 Dec;24(1):559-566. doi: 10.1080/16078454.2019.1642548.
4
MDS overlap disorders and diagnostic boundaries.骨髓增生异常综合征重叠疾病和诊断界限。
Blood. 2019 Mar 7;133(10):1086-1095. doi: 10.1182/blood-2018-10-844670. Epub 2019 Jan 22.
5
Immune-mediated bone marrow failure in C57BL/6 mice.C57BL/6小鼠的免疫介导性骨髓衰竭
Exp Hematol. 2015 Apr;43(4):256-67. doi: 10.1016/j.exphem.2014.12.006. Epub 2014 Dec 30.
6
Aplastic anemia: therapeutic updates in immunosuppression and transplantation.再生障碍性贫血：免疫抑制和移植治疗的最新进展。
Hematology Am Soc Hematol Educ Program. 2012;2012:292-300. doi: 10.1182/asheducation-2012.1.292.
7
Supportive care in severe and very severe aplastic anemia.再生障碍性贫血的支持治疗。
Bone Marrow Transplant. 2013 Feb;48(2):168-73. doi: 10.1038/bmt.2012.220. Epub 2012 Dec 3.
8
How I treat acquired aplastic anemia.我如何治疗获得性再生障碍性贫血。
Blood. 2012 Aug 9;120(6):1185-96. doi: 10.1182/blood-2011-12-274019. Epub 2012 Apr 19.
9
Clinical management of aplastic anemia.再生障碍性贫血的临床管理。
Expert Rev Hematol. 2011 Apr;4(2):221-30. doi: 10.1586/ehm.11.11.
10
Incidence of adult acquired severe aplastic anemia was not increased in Shanghai, China.在中国上海，成人获得性重度再生障碍性贫血的发病率并未上升。
Ann Hematol. 2011 Oct;90(10):1239-40. doi: 10.1007/s00277-011-1168-5. Epub 2011 Feb 2.